Sequencing Immunotherapy in Advanced-Stage Lung Cancer
Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing immunotherapy agents in advanced-stage lung cancer.<br />
Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing immunotherapy agents in advanced-stage lung cancer.
There had been a lot of debate about the timing of when patients should receive a PD-1 inhibitor, Garon explains.
Results of the KEYNOTE-024 study ended that debate when they showed patients with high levels of staining for PD-L1 were more likely to have an improvement in progression-free survival (PFS) if they received pembrolizumab (Keytruda) over chemotherapy. Additionally, there was a survival advantage seen in patients who received the PD-1 inhibitor as their initial therapy.
There is now a debate once again with the approval of carboplatin, pemetrexed, and pembrolizumab, based on results of the KEYNOTE-021 study.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
